Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SUPN
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. for potential securities law violations. This follows the company's announcement that its Phase 2b study of SPN-820 for treatment-resistant depression did not meet its primary endpoint.
February 28, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals is under investigation for potential securities law violations after its SPN-820 study failed to meet primary endpoints.
The failure of the SPN-820 study is a significant setback for Supernus Pharmaceuticals, potentially affecting investor confidence and leading to legal challenges. This could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100